CITIC Securities says AIDD companies are generally at an early stage and the
industry may be entering an accelerated growth phase. It identifies three
commercial models in AI biotech: SAAS-only software providers; AI-enabled CROs
offering drug screening and evaluation services; and AI-originator drug
companies that use platforms to design drugs and advance pipelines. Most firms
currently combine models and the overall AI drug market remains small, but
greater capital inflows, technology iteration and validation as AI drug
pipelines reach the market should support a transition to a harvest/accelerated
growth period.